data
Article
Demonstration Study: A Protocol to Combine Online
Tools and Databases for Identifying Potentially
Repurposable Drugs
AditiChattopadhyay1andMadhaviK.Ganapathiraju2,*
1 Grade12,UpperSt.ClairHighSchool,Pittsburgh,PA15241,USA;aditic@verizon.net
2 DepartmentofBiomedicalInformaticsandIntelligentSystemsProgram,UniversityofPittsburgh,
Pittsburgh,PA15206,USA
* Correspondence:madhavi@pitt.edu
AcademicEditor:PufengDu
Received:8October2016;Accepted:25April2017;Published:4May2017
Abstract: Traditional methods for discovery and development of new drugs can be very
time-consumingandexpensiveprocessesbecausetheyincludeseveralstages,suchascompound
identification, pre-clinical and clinical trials before the drug is approved by the U.S. Food and
DrugAdministration(FDA).Therefore,drugrepurposing,namelyusingcurrentlyFDA-approved
drugsastherapeuticsforotherdiseasesthanwhattheyareoriginallyprescribedfor,isemerging
tobeafasterandmorecost-effectivealternativetocurrentdrugdiscoverymethods. Inthispaper,
we have described a three-step in silico protocol for analyzing transcriptomics data using online
databases and bioinformatics tools for identifying potentially repurposable drugs. The efficacy
ofthisprotocolwasevaluatedbycomparingitspredictionswiththefindingsoftwocasestudies
of recently reported repurposed drugs: HIV treating drug zidovudine for the treatment of dry
age-relatedmaculardegenerationandtheantidepressantimipramineforsmall-celllungcarcinoma.
Theproposedprotocolsuccessfullyidentifiedthepublishedfindings,thusdemonstratingtheefficacy
ofthismethod. Inaddition,italsoyieldedseveralnovelpredictionsthathavenotyetbeenpublished,
includingthefindingthatimipraminecouldpotentiallytreatSevereAcuteRespiratorySyndrome
(SARS),adiseasethatcurrentlydoesnothaveanytreatmentorvaccine. Sincethisinsilicoprotocolis
simpletouseanddoesnotrequireadvancedcomputerskills,webelieveanymotivatedparticipant
withaccesstothesedatabasesandtoolswouldbeabletoapplyittolargedatasetstoidentifyother
potentiallyrepurposabledrugsinthefuture.
Keywords: drugrepurposing;translationalbioinformatics;transcriptomics;transcriptomeanalysis;
drugdiscovery;computationalprotocol;geneexpression
1. Introduction
Denovomethodsfordrugdiscoverycanbeincrediblyexpensiveandtimeconsuming. Atarget
molecule, such as a gene that is causally linked to a disease, is first identified to initiate the drug
discoveryprocess. Scientiststhensystematicallyscreenforsmallmoleculesthatmodulatethetarget
protein-productandcarryoutaseriesofoptimizationstepstoimprovetheefficacyoftheleaddrug.
Next, periods of animal studies are followed by clinical trials before a drug can be approved for
themarketbytheUSAFoodandDrugAdministration(FDA)(oritscounterpartinothercountries).
Usually, this procedure costs four to 12 billion dollars and takes an average of 12 to 17 years to
complete[1]. Unfortunately,insomecases,thismaynotresultinanysuccessfuldrugthatissafefor
humanuse. Forexample,ifapromisingdrugstartstorevealseveresideeffectsduringclinicaltrials,
Data2017,2,15;doi:10.3390/data2020015 www.mdpi.com/journal/data
Data2017,2,15 2of11
thedrugisdiscarded,andtheresourcesinvestedwouldthusbewasted. Duetotheselimitations,only
50newdrugscouldbeapprovedbytheU.S.FDAduringaperiodoftenyearsfrom1999to2008[2].
In order to make the current drug discovery practices more efficient or productive, a new
approach based on repurposing the existing FDA-approved drugs for new diseases has recently
gained traction [1]. Drug repurposing, which is typically based on systems biology and data
analytics, could drastically reduce both the cost and time associated with finding suitable drugs
for diseases. There are several drugs that were successfully repurposed to treat new diseases [3],
ofwhichsomewell-knownexamplesinclude: anti-anginadrugsildenafilcitraterepurposedtotreat
erectiledysfunction[4],thediabetesmedicinemetforminthathaspotentialuseforcancertreatment[5],
HIV drug nucleoside reverse transcriptase inhibitors that could treat “dry” age-related macular
degeneration[6]andimipramine, atricyclicantidepressant, withpotentialtotreatsmall-celllung
carcinoma[7].
A common method of identifying repurposed drugs is based on the following principle.
Human cells maintain homeostasis through the regulated expression of their transcriptome.
Aperturbationofcellulargeneexpressionoftenleadstothemanifestationofadiseasestate;hence,
each disease normally reveals a signature gene expression profile [8]. When a suitable drug is
administered to treat a disease, it tends to correct the aberration by bringing the gene expression
patternbacktoitsnormalstate. Thus,anegativecorrelationisgenerallyrevealedbetweenthegene
expressionsignaturesofthedrugandthedisease[8,9]. Aschematicdiagramrepresentingopposing
geneexpressionpatternsunderadiseasestateandunderitsdrugtreatmentisshowninFigure1.
Figure1. Acontrastinggeneexpressionpatternbetweenstudies: “diseasevs. normal”and“drug
treatmentvs. untreated.”Redcoloredbarsindicateover-expressionofgenes,whilegreen-colored
barsrepresentsunder-expressedgenes.(A)Differentialexpressionofgenesindisease.(B)Opposing
differentialexpressionduetoadministeringadrug(relativeto‘normal’expression).
Advancements in high-throughput technologies, such as microarrays and RNA-sequencing
methods,allowscientiststomeasuregeneexpressionpatternsunderdifferentexperimentalconditions.
Data2017,2,15 3of11
Scientists routinely deposit gene expression data derived from such experiments into online
repositories,oftentimesmakingthedatafreelyavailable[10].
Publishedstudieshaveshownthatthestatisticalanalysisofgeneexpressiondatacanbeutilized
toidentifyrepurposabledrugs[8]. However,runningthesesophisticatedcorrelationstatisticsongene
expressiondatasetsrequiresproficiencyinthefieldsofcomputerscience,bioinformaticsandstatistics,
alongwithaccesstohighpoweredcomputers. Theadventofbioinformaticstoolsthatminerawgene
expressiondatafromtherepositoryandrunsophisticatedstatisticalalgorithmsplaysanimportant
roleinmakingpre-processedtranscriptomicsdataavailabletothepublic.
Wehavedevelopedaprotocolbysequentiallyconnectingdisparateexistingonlinebioinformatics
tools,databasesandliteraturesearchenginestoidentifyrepurposabledrugs. Thisprotocol,whichcan
beusedbyanymotivatedindividual,takesanFDAapproveddrugastheinputandthensearchesfor
diseasesthatshownegativelycorrelatedgeneexpressioninrelationtothatdrug. Theefficacyofthis
protocolwasassessedbycomparingtheprotocolpredictionwiththeresultsoftworecently-published
articlesofrepurposeddrugs: zidovudine[6]andimipramine[7].
2. Methods
2.1. BaseSpaceCorrelationEngine
TheBaseSpaceCorrelationEngine,formerlyNextBio,isasearchableonlinedatabasemaintained
anddeliveredbyIlluminaInc.,SanDiego,CA,USA(https://www.nextbio.com/)[11]. Thisdatabase
collectsrawexperimentaldatafromhigh-throughputgeneexpressionexperimentssubmittedtoglobal
repositories,suchastheGeneExpressionOmnibus(GEO,http://www.ncbi.nlm.nih.gov/geo/)and
ArrayExpress(https://www.ebi.ac.uk/arrayexpress/).
The BaseSpace Correlation Engine utilizes proprietary statistical algorithms to convert raw
experimental data into a list of genes that are differentially expressed in certain conditions along
with their corresponding fold change and p-value calculations. The fold change value indicates
howagivengeneisdifferentiallyexpressedinatestconditioncomparedtothecontrolconditionof
anexperiment. Examplesareexperimentswithdrugtreatmentvs. non-treatmentordiseasestatevs.
normalstate.Rank-basedenrichmentstatisticsarethenusedtocomputethepairwisecorrelationscores
betweenallgeneexpressionsignaturespresentinthedatabase. Themostcorrelatedgeneexpression
study present for each query was assigned a numerical score of 100, and scores for the rest of the
resultswerenormalizedtothetop-rankedstudy. Thisresourceenablesuserstofindgeneexpression
experimentswithgivendrug-treatedversusuntreatedconditions. Hence,diseasesshowingstrong
negativecorrelationwithagivendrugcanbeidentifiedtopredictpotentiallyrepurposabledrugs.
2.2. PubMed
Anonlinedatabase(https://www.ncbi.nlm.nih.gov/pubmed)iscomprisedofover26million
citationspublishedin2600lifesciencesjournals. Manyofthesecitationsprovidelinkstotheabstract
andfulltextofthearticle. ThisdatabaseisfreelyaccessibleandmaintainedbytheNationalLibraryof
Medicine,adivisionoftheU.S.NationalInstituteofHealth.
2.3. InSilicoProtocoltoIdentifyRepurposedDrugs
Aprotocolencompassingthesystematicsearchoftheonlinedatabasesmentionedaboveenables
userstoquicklyandefficientlyidentifypotentialtargetdiseasesforadrug(Figure2). Thestepsare
asfollows:
a. Identifygeneexpressionstudiesassociatedwiththedrug:
EnteradrugnameinthesearchboxoftheBaseSpaceCorrelationEngineandthenclickonthe
iconnamed“CuratedStudies”displayedatthetopofthewebpage. Oncethesearchresultisreturned,
Data2017,2,15 4of11
click on the “Filter By” option and select “Data Types” available at the top of the page and select
“RNAExpression.”
Browse the search results returned that will display numerous independent gene expression
studies. Identify the studies that compare the gene expressed data for drug treatment vs. control
(untreated). Selecttheappropriatestudybyclickingonthehyperlinkofthatstudy. Eachstudymay
have multiple experiments measured under different conditions such as a different dosage of the
drugordifferenttreatmenttimepoints. Clickingonthestudywillbringupapagewithadetailed
descriptionofthestudy,aswellaslinkstothegeneexpressiondataassociatedwitheachexperiment.
When the experiment was selected by clicking the hyperlinked title and a table consisting of the
differentialgeneexpression,datawillappearonthescreen.
b. Searchfordiseaseswithnegativecorrelations:
Selecttheicon“DiseaseAtlas”availableatthetopofthepage. Awebpagedisplayingatableof
variousdiseasenameswiththeircorrespondingcorrelationscoreswillappear. Sortthroughthetable
byselecting“Rank”fromthedrop-downmenuavailableunderthe“ViewBy”optiondisplayedatthe
topleftcornerofthepage. Re-sorttheresultsbyselectingthe“−veCorrelation”optionpresentinthe
drop-downmenuunderthe“CorrelationwithQuery”columnheadingatthetopoftheright-most
column. Finally,selectthediseasesthathavethelargestnumberofstudies. Thequerieddrugwould
havethepotentialtotreattheselecteddiseases.
c. Searchliteraturedatabasetovalidatediseasepredictions:
GotoPubMed,andenter“thedrugnameANDthepredicteddiseasename”inthesearchbox
andlookforcitations.
Figure2.Athree-steponlineprotocolforrepurposeddrugprediction.
3. Results
This protocol was applied to two previously published repurposed drugs, and the protocol
predictionswerecomparedwiththereportedfindings.
3.1. CaseStudy1: Zidovudine
Through experiments performed in mouse models, Fowler et al. reported that the drug
zidovudine,aNucleosideReverseTranscriptaseInhibitor(NRTI)usuallyusedtotreatHIVpatients,
showed strong potential to be used against the untreatable dry form of Age-related Macular
Degeneration(AMD)[6].
Data2017,2,15 5of11
3.1.1. StudySelectionfromtheBaseSpaceCorrelationEngine
AsearchforcuratedstudiesusingthequeryzidovudineintheBaseSpaceCorrelationEngine
retrieved10RNA-expressionstudies: sixstudiesbasedonratexperimentsandfourfromexperiments
doneonhumandata. Astudytitled“DrugMatrixInVitroToxicogenomicStudy—RatHepatocytes
[Affymetrix]”[12,13]wasselectedforfurtheranalysis. Althoughdrug-treatmentstudiesperformed
onnormalhumancelllineswouldbepreferredforrepurposeddiseaseprediction,forthisquery,all
humanstudieswereonlycarriedoutforcancercelllinesorvirus-infectedcells. Hence,theywerenot
suitableforstudyselection. Ontheotherhand,thestudiesbasedonratexperimentswereperformed
undernormalconditions. Sincetheliverisaprincipalsiteofdrugmetabolism,astudymeasuringthe
geneexpressionpatternsofrathepatocytecellswasselected.
In this study, rat hepatocyte cells isolated from male Sprague-Dawley rats were co-cultured
invitrowithvaryingdosesofthedrugduringdifferenttimepoints. Microarrayexperimentswere
then performed on an Affymetrix platform to measure and compare the gene expression patterns
oftreatmentversuscontrolconditions. Typically,ageneexpressionstudyiscomprisedofmultiple
experiments. Amongthethreeexperimentslistedunderthisstudy,theexperimenttitled“Primary
rathepatocytes+ZIDOVUDINEat14,800µMinDMSO1D_vs_vehicle”coveredthelargestnumber
of genes (8000). Therefore, the differentially-expressed gene (DEG) profile of the said experiment
was used as a query to seek out Negatively-Correlated (NC) diseases for zidovudine. Figure 3
showsascreenshottakenfromtheBaseSpaceCorrelationEngineresultpagedisplayingthetopten
differentially-expressedgenes.
Figure3.AscreenshottakenfromtheBaseSpaceCorrelationEngine-generatedresultpagedisplaying
thetoptendifferentially-expressedgenesoftheselectedquerystudy: zidovudinetreatmentonrat
hepatocytecellsvs.untreatedcells.
Data2017,2,15 6of11
3.1.2. Negatively-CorrelatedDiseases
TheBaseSpaceCorrelationEngineranksthenegatively-correlateddiseasesbasedonitsassigned
correlationscore. Themostcorrelatedgeneexpressionstudy,withthelowestp-value,presentforeach
queryisassignedanumericalscoreof100andscoresfortherestoftheresultswerenormalizedto
thetop-rankedstudy. However,forthisprotocol,therankingwasmanuallychangedtoreflectthe
numberofsupporting,independentstudies. Thisstepwastakentobolsterthepredictionefficiency
withthenotionthatifmoreindependentexperimentsfoundanegativecorrelationbetweenthedrug
andthedisease,thenitsrankingshouldbestronger(whilestillmaintaininganacceptablescoreofat
least50/100tokeepcorrelationasafactor). Table1showsthetop10negatively-correlateddiseasesfor
HIV-drugzidovudineorderedbythenumberofsupportedgeneexpressionstudies.
Amongthediseaseslistedinthetable,humanimmunodeficiencyvirusinfection,theintended
targetofzidovudine,ispresent(No. 5). Thegeneexpressionprofilesderivedfromtwenty-onestudies
revealedastrongstatistically-significantnegativecorrelation(score: 62)withtheexpressionpattern
ofzidovudine.
Table1. Top10negatively-correlateddiseasesforHIV:drugzidovudineorderedbythenumberof
supportedgeneexpressionstudies.
NumberofSupporting CorrelationScore Published
NegativelyCorrelated
StudiesinBaseSpace DeterminedbyBaseSpace Supporting
Disease
CorrelationEngine CorrelationEngine LiteratureinPubMed
1.LupusErythematosus 45 65 Yes[14]
2.CardiovascularDiseases 26 54 No
3.LymphoidLeukemia 25 58 Yes[15]
4.Neuropathy 24 65 No
5.HumanImmunodeficiency
21 62 Yes[6]
VirusInfection
6.Mycobacteriosis 19 67 No
7.RheumatoidArthritis 19 58 No
8.Myopathy 17 64 No
9.RetinalDisorder 17 60 Yes[6]
10.Dermatitis 17 50 No
Figure 4 displays a comparison of gene expressions between the query experiment and the
experiment“CD8+TcellsfromchronicHIVinfectionpatients_vs_negativecontrol”listedunder
the study “HIV-infected individuals with various clinical stages of HIV infection” performed by
Hyrczaetal.[16].SincetheprotocolcorrectlypredictedthatzidovudinecouldtreatHIV,itsintended
target,thisfindingservesasavaluableresulttoprovetheefficacyofthisprotocol.
ForAge-relatedMacularDegeneration(AMD),thepublishedfinding[6]thatwesoughtfalls
under the broader term “retinal disorder,” which is present in the list of the NC diseases (No. 9).
TheDEGprofileoftheexperiment“Macularretina—GAAge-relatedmaculardegenerationvs. normal
tissue”aspartofthestudy“Age-relatedmaculardegenerationsubtypeexpressionanalysis”revealed
astrongnegativecorrelationwiththegeneexpressionprofileofzidovudine[17].
ApartfromHIV,theintendedtargetofzidovudine,allotherNCdiseasesarenovelfindings,as
theyarenotlistedasatherapeutictargetofzidovudineinwell-knowndruginformationresources,
suchasDrugBank[18]andtheNationalLibraryofMedicineDrugInformationPortal[19]. Whilethe
potentialofthisdrugtotreatAMDhasbeenrecentlypublished,aliteraturesearchwasconducted
to collect evidence on whether the other NC diseases found have been connected to zidovudine.
AliteraturesearchfoundMarcaisetal. reportedthatthetreatmentofzidovudineishighlyeffectivein
thetreatmentofaleukemicsubtypeofadultt-celllymphoma[15]. Furthermore,Beck-Engeseretal.
publishedapaperontheefficacyofzidovudinetreatmentagainstlupuserythematosus[14]. However,
noliteratureevidencewasfoundforcardiovasculardisease,neuropathy,mycobacteriosis,rheumatoid
arthritis,myopathyordermatitis.
Data2017,2,15 7of11
Figure 4. A screenshot was taken from the BaseSpace Correlation Engine showing
a statistically-significant negative correlation among differentially-expressed genes from two
experiments: “CD8+TcellsfromacuteHIV-infectedpatients’vsnegativecontrol”andthequery
study“Zidovudinetreatmentonrathepatocytevs.negativecontrol(vehicletreatedcells).”
3.2. CaseStudy2: Imipramine
In2013,JahchanandcolleaguesreportedthattheTricyclicAntidepressant(TCA)imipramine
could be efficiently repurposed to treat small-cell lung carcinoma [7]. In a protocol of their own,
thisstudysoughtsmallmoleculeswiththeabilitytotreattheapparentlyrecalcitrantformoflung
cancerfirstbyanalyzingthedisease-derivedtranscriptomicdataandthenbyrunningexperimentsin
ananimalmodel. Oneofthesmallmoleculesidentifiedwasimipramine.
3.2.1. Study/ExperimentSelectionfromBaseSpaceCorrelationEngine
A search for Imipramine (performed on 20 June 2016) in the BaseSpace Correlation Engine
resultsineightstudies. TheDEGprofilederivedfromtheexperimenttitled“Hepatocytesoffemale
donors treated 24hr with 15uM imipramine _vs_ 0uM” done in human as a part of the study
“GenomicsAssistedToxicityEvaluationsystemstudy—HumanHepatocytes”wasselectedfortarget
diseasepredictionthroughthisprotocol[20].
3.2.2. NegativelyCorrelatedDiseases:
AlistofNCdiseasesbasedontheDEGprofileexpressedbytheselectedqueryexperimentis
presentedinTable2. Thelistshowsapreponderanceofcancersubtypes. Notethatsmall-celllung
carcinoma, the reported therapeutic target for imipramine, is present in the NC disease list under
lungcancer(No. 3). Hence,thefindingsreportedbyJahchanetal.[7]weresuccessfullyreplicatedby
thisinsilicoprotocol. Aliteraturesearchonimipramineretrievedpreviouslypublishedarticlesthat
studiedthetreatmentofimipramineontwoofthepredictedtargetdiseases: breastcancer[21]and
Data2017,2,15 8of11
braincancer[22]. However,nosupportingevidencefromtheliteraturewasfoundforthetreatment
oflivercancer,kidneycancer,inflammatoryboweldiseaseorSevereAcuteRespiratorySyndrome
(SARS)usingimipramine. ThepredictionofSARSisnotablebecauseitrevealedthehighestcorrelation
scoreof100. However,thelackofreportedevidenceontherepositioningofimipramineagainstSARS
furtheremphasizesthenoveltyofthisprediction.
Table2.Top10negatively-correlateddiseasesorderedbythenumberofsupportedgeneexpression
studiesforantidepressantimipramine.
Numberof CorrelationScore Published
SupportingStudies Determinedby Supporting
NegativelyCorrelatedDisease
inBaseSpace BaseSpaceCorrelation Literaturein
CorrelationEngine Engine PubMed
BreastCancer 57 65 Yes[21]
AllergicDisorder 50 65 Yes[23]
LungCancer 49 65 Yes[7]
LiverCancer 47 65 No
BrainCancer 44 66 Yes[22]
InflammatoryBowelDisease 32 66 No
Cardiomyopathy 28 68 No
KidneyCancer 26 68 No
NerveInjury 23 79 Yes[24]
SevereAcuteRespiratorySyndrome 14 100 No
4. Conclusions
Wehavebeenabletoverifythefindingsofpreviouslyreportedresultsfortwodrugs: HIV-drug
zidovudine and tricyclic antidepressant drug imipramine. Through this protocol, HIV-treating
drug zidovudine was found to have the potential to be repurposed as a drug for dry age-related
macular degeneration [17] along with several other diseases, including lupus erythematosus,
cardiovasculardisease,lymphoidleukemia,neuropathy,mycobacteriosis,rheumatoidarthritisand
dermatitis. Amongthese,fourofthefindingsweresupportedbyevidencefrompublishedliterature.
Imipraminecouldhavethepotentialtotreatsmall-celllungcarcinoma[7]. Furthermore,wefoundthat
imipraminehasthepotentialtotreatseveralotherdiseases,includingbreastcancer,allergicdisorder,
livercancer,braincancer,inflammatoryboweldisorder,cardiomyopathy,kidneycancer,nerveinjury
andSevereAcuteRespiratorySyndrome(SARS).Fiveoftheresultsfoundhavebeensupportedwith
publishedliterature.
5. Limitations
This online repurposed drug prediction protocol depends on the availability of access to the
BaseSpaceCorrelationEngineanditsanalysisoftranscriptomicsdata. Ifthedataforagivendrugare
notavailable,theprotocolcannotbeappliedtothatdrug.
Furthermore, the DEG data gathered from experiments that compare the effect of the drug
treatmentonanormal(non-diseased)humancelllineortissuetotheuntreatedorvehicletreated
conditionareconsideredtobeidealdatasetsforthismethod. However,formanydrugs,suchdatasets
arenotavailable. Instead,theavailableDEGdatacomefromexperimentsonhumancancercelllines
orfromexperimentsperformedonanimalmodels,suchasmouseandrat. Theprotocolutilizingthe
non-idealdatasetmayinfererroneouspredictionsandrequiringadditionalanalysis.
TheBaseSpaceCorrelationEnginewasfreelyavailabletotheresearchcommunity,andtheauthors
receivedfreeaccessuponrequesttothevendor. However,currently,thetoolrequirespaidsubscription
withafifteen-dayfreetrialoption.
Data2017,2,15 9of11
6. Discussion
Thecasestudiesmentionedheresubstantiatethetargetdiseasepredictionaccuracyforadrugby
thisprotocol. Thefindingthatimipraminecouldberepurposedtotreatsmall-celllungcancerwas
anexpectedfindingastranscriptomicsdataanalysiswasemployedbyboththeliteraturedescribed
methods,aswellasbythisinsilicoprotocol. However,thecorrectpredictionthatthedryformof
AMDmaybeatargetdiseaseisnoteworthybecausetheunderlyingdiscoverymethodsweredifferent.
The literature [6] used a small molecule screening technique, while this in silico protocol applied
transcriptomics data analysis. This finding further adds credence to the strategy adopted by this
protocoltopredictdiseasesagivendrugcanberepurposedtoward.
ThepredictionthatimipraminecouldberepurposedagainstSARSisasignificantobservation.
SARS is a deadly viral disease, and during the period of 2002 to 2003, an outbreak caused over
8000caseswith772deathsreportedin37countries[25]. Asoftoday,thereisnotreatmentorvaccines
availableforSARS.Thismakesthepredictionsmadebythisprotocolparticularlyadvantageousfor
such deadly diseases by giving patients a possible treatment [26]. Because this is a novel finding,
furtherclinicalinvestigationmeasuringthepotencyofimipramineagainstSARSinhumanwould
beneeded.
The in silico protocol described in this study leverages pre-processed transcriptomics data
available through the BaseSpace Correlation Engine database. This method is straight forward,
simpletouseanddoesnotrequireadvancedcomputerskills. Hence,itmaybebeneficialtousers
includingresearchers,clinicians,patientsandevenhighschoolstudentswhocanapplythismethod
andidentifytheexistingdrugsthatcanberepurposedtoserveasnewtherapeutictargetsforvarious
diseases in the future. We hope this protocol could be utilized as a crowdsourcing tool for drug
discoveryresearch.
7. CitizenScience
Thisworkdescribesaprotocolbywhichexistingtoolsanddatabasescanbeutilizedtodrawnovel
resultsthroughhumancomputation. Wehopethatintheeventofepidemics,suchasviralinfections
ortransmittablediseases,theglobalscientificcommunity,especiallyhighschoolandundergraduate
students, could employ this protocol to shortlist drugs that may be useful. We created an online
formwheretheoutcomesofsuchcitizensciencecouldbecollected. Theonlineformisavailableat
http://severus.dbmi.pitt.edu/SSDR. Uponreceivingsubmissionswiththisform,wewillpostthem
forworld-wideuserstoviewthemonaseparatepageunderthesamewebsite.
Author Contributions: AC is a high school student (12th grade) and carried out this work and wrote the
manuscriptwithsupervisionfromMKG.Themanuscripthasbeenreadandapprovedbybothauthors.
ConflictsofInterest:Theauthorsdeclarethattheydonothaveanyconflictofinterest.
References
1. Hurle,M.R.; Yang,L.; Xie,Q.; Rajpal,D.K.; Sanseau,P.; Agarwal,P.Computationaldrugrepositioning:
Fromdatatotherapeutics.Clin.Pharmacol.Ther.2013,93,335–341.[CrossRef][PubMed]
2. Swinney,D.C.;Anthony,J.Howwerenewmedicinesdiscovered?Nat.Rev.DrugDiscov.2011,10,507–519.
[CrossRef][PubMed]
3. Chong,C.R.;Sullivan,D.J.Newusesforolddrugs.Nature2007,448,645–646.[CrossRef][PubMed]
4. Ghofrani,H.A.;Osterloh,I.H.;Grimminger,F.Sildenafil:Fromanginatoerectiledysfunctiontopulmonary
hypertensionandbeyond.Nat.Rev.Drug.Discov.2006,5,689–702.[CrossRef][PubMed]
5. Morales,D.R.;Morris,A.D.Metforminincancertreatmentandprevention.Annu.Rev.Med.2015,66,17–29.
[CrossRef][PubMed]
6. Fowler,B.J.;Gelfand,B.D.;Kim,Y.;Kerur,N.;Tarallo,V.;Hirano,Y.;Amarnath,S.;Fowler,D.H.;Radwan,M.;
Young,M.T.;etal.Nucleosidereversetranscriptaseinhibitorspossessintrinsicanti-inflammatoryactivity.
Science2014,346,1000–1003.[CrossRef][PubMed]
Data2017,2,15 10of11
7. Jahchan, N.S.; Dudley, J.T.; Mazur, P.K.; Flores, N.; Yang, D.; Palmerton, A.; Zmoos, A.-F.; Vaka, D.;
Tran,K.Q.T.;Zhou,M.;etal.Adrugrepositioningapproachidentifiestricyclicantidepressantsasinhibitors
ofsmallcelllungcancerandotherneuroendocrinetumors.CancerDiscov.2013,3,1364–1377.[CrossRef]
[PubMed]
8. Sirota,M.;Dudley,J.T.;Kim,J.;Chiang,A.P.;Morgan,A.A.;Sweet-Cordero,A.;Sage,J.;Butte,A.J.Discovery
andpreclinicalvalidationofdrugindicationsusingcompendiaofpublicgeneexpressiondata.Sci.Transl.
Med.2011,3,96ra77.[CrossRef][PubMed]
9. Iorio, F.; Bosotti, R.; Scacheri, E.; Belcastro, V.; Mithbaokar, P.; Ferriero, R.; Murino, L.; Tagliaferri, R.;
Brunetti-Pierri, N.; Isacchi, A.; et al. Discovery of drug mode of action and drug repositioning from
transcriptionalresponses.Proc.Natl.Acad.Sci.USA2010,107,14621–14626.[CrossRef][PubMed]
10. Barrett, T.; Wilhite, S.E.; Ledoux, P.; Evangelista, C.; Kim, I.F.; Tomashevsky, M.; Marshall, K.A.;
Phillippy, K.H.; Sherman, P.M.; Holko, M.; et al. NCBI GEO: Archive for functional genomics data
sets–update.Nucl.Acid.Res.2013,41,D991–D995.[CrossRef][PubMed]
11. Kupershmidt,I.;Su,Q.J.;Grewal,A.;Sundaresh,S.;Halperin,I.;Flynn,J.;Shekar,M.;Wang,H.;Park,J.;
Cui,W.;etal.Ontology-basedmeta-analysisofglobalcollectionsofhigh-throughputpublicdata.PLoSONE
2010,5,e13066.[CrossRef][PubMed]
12. Natsoulis,G.;Pearson,C.I.;Gollub,J.;PEynon,B.;Ferng,J.;Nair,R.;Idury,R.;Lee,M.D.;Fielden,M.R.;
Brennan,R.J.;etal.Theliverpharmacologicalandxenobioticgeneresponserepertoire.Mol.Syst.Biol.2008,
4,175.[CrossRef][PubMed]
13. Waters,M.;Stasiewicz,S.;AlexMerrick,B.;Tomer,K.;Bushel,P.;Paules,R.;Stegman,N.;Nehls,G.;Yost,K.J.;
Johnson,C.H.;etal. CEBS–ChemicalEffectsinBiologicalSystems: Apublicdatarepositoryintegrating
studydesignandtoxicitydatawithmicroarrayandproteomicsdata.Nucl.Acid.Res.2008,36,D892–D900.
[CrossRef][PubMed]
14. Beck-Engeser, G.B.; Eilat, D.; Wabl, M. An autoimmune disease prevented by anti-retroviral drugs.
Retrovirology2011,8,91.[CrossRef][PubMed]
15. Marçais,A.;Suarez,F.;Sibon,D.;Frenzel,L.;Hermine,O.;Bazarbachi,A.Therapeuticoptionsforadult
T-cellleukemia/lymphoma.Curr.Oncol.Rep.2013,15,457–464.[CrossRef][PubMed]
16. Hyrcza, M.D.; Kovacs, C.; Loutfy, M.; Halpenny, R.; Heisler, L.; Yang, S.; Wilkins, O.; Ostrowski, M.;
Der,S.D.DistincttranscriptionalprofilesinexvivoCD4+andCD8+Tcellsareestablishedearlyinhuman
immunodeficiencyvirustype1infectionandarecharacterizedbyachronicinterferonresponseaswellas
extensivetranscriptionalchangesinCD8+Tcells.J.Virol.2007,81,3477–3486.[CrossRef][PubMed]
17. Newman, A.M.; Gallo, N.B.; Hancox, L.S.; Miller, N.J.; Radeke, C.M.; Maloney, M.A.; Cooper, J.B.;
Hageman, G.S.; Anderson, D.H.; Johnson, L.V.; et al. Systems-level analysis of age-related macular
degenerationrevealsglobalbiomarkersandphenotype-specificfunctionalnetworks.GenomeMed.2012,4,
16.[CrossRef][PubMed]
18. Wishart, D.S.; Knox, C.; Guo, A.C.; Shrivastava, S.; Hassanali, M.; Stothard, P.; Chang, Z.; Woolsey, J.
DrugBank:Acomprehensiveresourceforinsilicodrugdiscoveryandexploration.Nucl.Acid.Res.2006,34,
D668–D672.[CrossRef][PubMed]
19. DrugInformationPortal—U.S.NationalLibraryofMedicine—QuickAccesstoQualityDrugInformation
[Internet]. Available online: https://druginfo.nlm.nih.gov/drugportal/drugportal.jsp (accessed on
18September2016).
20. Uehara, T.; Ono, A.; Maruyama, T.; Kato, I.; Yamada, H.; Ohno, Y.; Urushidani, T. The Japanese
toxicogenomicsproject:applicationoftoxicogenomics.Mol.Nutr.FoodRes.2010,54,218–227.[CrossRef]
[PubMed]
21. Rajamanickam,S.;Panneerdoss,S.;Gorthi,A.;Timilsina,S.;Onyeagucha,B.;Kovalskyy,D.;Ivanov,D.;
Hanes,M.A.;Vadlamudi,R.K.;Chen,Y.;etal.InhibitionofFoxM1-MediatedDNARepairbyImipramine
BlueSuppressesBreastCancerGrowthandMetastasis. Clin. CancerRes. 2016,22,3524–3536. [CrossRef]
[PubMed]
22. Shipman,L.Glioma: Repurposeddrugscombinedtoamplifyautophagy. Nat. Rev. Cancer2015,15,636.
[CrossRef][PubMed]
23. Hama,A.T.;Borsook,D.Theeffectofantinociceptivedrugstestedatdifferenttimesafternerveinjuryinrats.
AnesthAnalg.2005,101,175–179.[CrossRef][PubMed]
Data2017,2,15 11of11
24. Sugar, J.; Nyberg, M.; Bernstein, J.; Barlow, A.; Slater, W. Imipramine inhibition of ragweed allergic
conjunctivitis.InvestOphthalmol.Vis.Sci.1984,25,217–218.[PubMed]
25. WHO.SummaryofProbableSARSCasesWithOnsetofIllnessfrom1November2002to31July2003
[Internet]. Availableonline: http://www.who.int/csr/sars/country/table2004_04_21/en/(accessedon
10September2016).
26. Jiang,S.;Lu,L.;Du,L.DevelopmentofSARSvaccinesandtherapeuticsisstillneeded.FutureVirol.2013,8,
1–2.[CrossRef]
©2017bytheauthors. LicenseeMDPI,Basel,Switzerland. Thisarticleisanopenaccess
articledistributedunderthetermsandconditionsoftheCreativeCommonsAttribution
(CCBY)license(http://creativecommons.org/licenses/by/4.0/).
